Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Migalastat in Pediatric Subjects With Fabry Disease
NCT06904261Phase 3Recruiting
- Sponsor
- Amicus Therapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Classical Binding Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of migalastat in Fabry disease (FD), sponsored by Amicus Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT06904261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904261.